# Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

> **NCT00329043** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 64 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** LHRH Agonist
- **DRUG:** Sunitinib Malate
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT00329043
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2006-05-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329043, "Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00329043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*